SUBSCRIBE
Login
Back to all insights

EMA Confirms Suicidal Thoughts with Finasteride — Detailed summary, implications, and a practical pharmacovigilance / manufacturer action plan

Looking For Service?

Source documents: EMA PRAC communications and referral page (May–June 2025). European Medicines Agency (EMA)+1

Executive summary — the one-minute version

  • The European Medicines Agency’s safety committee (PRAC) has confirmed suicidal ideation (suicidal thoughts) as an adverse effect of finasteride (both 1 mg—used for hair loss—and 5 mg—used for BPH). The frequency is unknown from available data. European Medicines Agency (EMA)
  • The PRAC concluded that benefits continue to outweigh risks for approved uses, but new risk-minimisation measures were recommended (label updates, patient alert card for 1 mg packaging, Dear HCP letters). The CMDh endorsed the measures on 19 June 2025. European Medicines Agency (EMA)+1
  • For dutasteride, PRAC did not establish a causal link, but because it has the same mechanism of action, mood-change warnings similar to finasteride will be added as a precaution. European Medicines Agency (EMA)

What PRAC found (evidence & conclusions)

  • PRAC reviewed EU-wide data (spontaneous reports, literature, regulatory submissions) and found that reports of suicidal ideation—mostly in users of 1 mg finasteride (and some 5 mg users)—are sufficiently consistent to warrant adding suicidal ideation to the product information (SmPC). The committee could not reliably estimate an incidence rate from the available evidence. European Medicines Agency (EMA)
  • PRAC also considered mechanistic plausibility: sexual dysfunction (a recognised adverse effect of finasteride) may contribute to depressed mood and suicidal thoughts in some patients; neurosteroid pathway effects have been hypothesised in the literature. However, causality remains complex and multifactorial. PMCMedscape

Key regulatory changes and public health measures

  • SmPC and PIL updates: Suicidal ideation will be listed as a (new) adverse reaction for finasteride 1 mg and 5 mg; information on mood changes will be added to dutasteride. The PIL (patient leaflet) will instruct patients to stop finasteride 1 mg and seek medical help if they experience mood problems. European Medicines Agency (EMA)
  • Patient alert card: Finasteride 1 mg packages will include a patient-alert card summarising the risk and urging immediate contact with healthcare professionals for mood or sexual-function changes. European Medicines Agency (EMA)
  • Dear Healthcare Professional (DHPC) letter: Regulators will coordinate DHPCs instructing prescribers to screen, counsel, and act promptly if mood changes occur. Drug Office
  • CMDh endorsement: The Coordination group for Mutual recognition and Decentralised procedures — Human (CMDh) endorsed PRAC measures on 19 June 2025, signalling EU member states will implement the changes. European Medicines Agency (EMA)

Clinical and public-health implications (who should worry and what to do)

  • Patients on finasteride 1 mg (hair loss): heightened vigilance. They should be informed at initiation about mood and sexual-function risks, given the alert card, and told to stop treatment and seek medical advice if they experience depressed mood, depression or suicidal thoughts. European Medicines Agency (EMA)
  • Prescribers (GPs, dermatologists, urologists): review ongoing finasteride prescriptions, particularly in patients with current or prior psychiatric illness, suicidal ideation, or significant sexual dysfunction; discuss stopping therapy and consider alternative treatments. Document counselling and informed consent. Medscape
  • Dutasteride users: while causal link not established, clinicians should add counselling about mood changes as a precaution. European Medicines Agency (EMA)

Impact on manufacturers — regulatory & operational checklist

Manufacturers (brand and generics) must act quickly and comprehensively. Below are prioritized actions with practical detail.

1. Labeling & regulatory submissions (immediate → 4 weeks)

  • Prepare harmonised SmPC/PIL amendments to add suicidal ideation to the adverse reaction list for finasteride 1 mg and 5 mg; add mood-change language to dutasteride. Align wording with PRAC/CMDh recommendations. European Medicines Agency (EMA)
  • File variations/line extensions as required in each EU member state (or centralised procedure where relevant); tag submissions as safety updates and request expedited review. Provide proposed DHPC text for regulators to use. European Medicines Agency (EMA)

2. Risk-minimisation materials (days → 2 weeks)

  • Patient alert card: design per PRAC specifications (clear, short, icons), localise languages, and integrate into packaging for 1 mg packs. Begin distribution plan for existing stock (inserts or accompanying leaflets). European Medicines Agency (EMA)
  • DHPC / Dear HCP: prepare and offer to regulators a DHPC template that includes: summary of evidence, recommended screening questions, stop-and-seek advice, reporting instructions, and suggested documentation language. Drug Office

3. Pharmacovigilance enhancements (immediate and ongoing) — see dedicated PV plan below

  • Implement intensified monitoring (increased case follow-up, active surveillance studies, targeted disproportionality analyses) and prepare periodic safety update report (PSUR) supplements referencing PRAC actions. PMC

4. Medical affairs & sales/commercial (immediate)

  • Pause or stop promotional activity that suggests finasteride for off-label cosmetic uses without careful risk counselling. Update sales/materials and retrain medical liaisons on new safety messages. The Pharma Letter

5. Manufacturing / supply chain operations

  • Plan packaging runs and logistics to include patient-alert cards; implement quality checks to ensure new leaflets accompany all units in distribution during the transition. European Medicines Agency (EMA)

6. Legal & ethics

  • Update informed-consent templates for initiation of finasteride therapy; prepare Q&As and support for clinicians on medico-legal concerns. Prepare to engage with patient advocacy groups, and have a plan for case management if severe reactions are reported. PFS Foundation

Detailed pharmacovigilance action plan (operational, step-by-step)

The EMA decision requires manufacturers to step up active and passive surveillance and to generate evidence clarifying magnitude, timing, and risk factors. Below is a realistic, prioritized PV program you can implement now.

A — Immediate signal management (0–7 days)

  1. Signal confirmation & briefing pack
    • Assemble a PRAC submission-ready safety dossier summarising all Company Individual Case Safety Reports (ICSRs) of suicidal ideation/behaviour (with narratives, timelines, concomitant meds, psychiatric history, sexual-dysfunction onset), literature, and regulatory correspondence. European Medicines Agency (EMA)
  2. Enhanced follow-up of ICSRs
    • Retrieve missing info for all pending ICSRs: full medical records, psychiatry consult notes, suicide attempt details, dates of onset vs dose start/stop, concomitant antidepressant/antipsychotic use, prior psychiatric history, and outcome. Apply robust causality assessment (WHO-UMC / RUCAM-style adapted for psychiatric events). PMC
  3. Coding & database hygiene
    • Ensure all events are coded consistently (MedDRA Preferred Terms: “suicidal ideation”, “suicide attempt”, “depression”, “depressed mood”, “self-harm”, etc.) and flagged for expedited review. Run internal disproportionality (ROR/PRR) for finasteride vs all other drugs and vs 5-alpha-reductase inhibitors. PMC

B — Short term epidemiology & analytics (2–8 weeks)

  1. Observed-vs-expected (O/E) analyses
    • Use national/regional healthcare databases (e.g., CPRD, national claims, EHR platforms) to estimate observed rates of suicidal ideation/attempts in finasteride users within predefined risk windows (0–30, 31–90, 91–365 days) and compare with background rates matched by age/sex/comorbidity. Include both 1 mg and 5 mg cohorts. PMC
  2. Self-controlled case series (SCCS) / case-crossover studies
    • Prioritize SCCS to control fixed confounders—good for rare, sudden outcomes like suicide attempts. Define risk windows around treatment initiation and cessation. PMC
  3. Disproportionality in global spontaneous databases
    • Run disproportionality analyses in FAERS, EudraVigilance, WHO VigiBase stratified by age, indication (alopecia vs BPH), dose, and sex. Produce age-sex stratified RORs. PMC

C — Targeted active surveillance (1–6 months)

  1. Prospective cohort / registry
    • Set up an international prospective registry for new finasteride initiators (esp. 1 mg, males 18–40), collecting baseline psychiatric history, sexual function scores (IIEF or similar), and serial mood screening (PHQ-9) at baseline, 1, 3 and 6 months. Collaborate with dermatology/GP networks. PMC
  2. Nested case–control / matched cohort
    • Within large EHR, perform matched cohort studies comparing finasteride users with users of alternative hair-loss treatments and with non-users, adjusting for confounders (socioeconomic status, prior mental health history). PMC

D — Mechanistic & clinical research (3–12 months)

  1. Biological plausibility work
    • Fund or collaborate on small studies examining neurosteroid levels, neuroimaging, or pharmacogenomics in patients who developed mood changes on finasteride to explore mechanisms. PMC
  2. Case series synthesis & expert review
  • Convene an independent panel (psychiatrists, neurologists, dermatologists, epidemiologists) to review anonymised case narratives and provide clinical interpretation.

E — Ongoing regulatory reporting & risk management (continuous)

  1. PSUR / RMP updates
  • Submit interim PSUR addenda and update the Risk Management Plan (RMP) with new signal characterization, planned studies, and communication materials. European Medicines Agency (EMA)
  1. Timely communications to HCPs & patients
  • Support regulators in distributing DHPC; publish company Q&As, site-specific guidance for psychiatrists and dermatologists, and hotline support for clinicians managing affected patients.

Suggested monitoring metrics & KPIs (for PV dashboards)

  • Number of new ICSRs with PT “suicidal ideation” per week (stratified by dose/indication)
  • Percentage of ICSRs with complete follow-up (medical records obtained) within 14 days
  • ROR/PRR values across spontaneous databases monthly
  • Enrollment numbers and retention in prospective registry (target N per country)
  • Time to submission for PSUR/RMP addenda (days)
  • Number of DHPCs distributed and HCP acknowledgement rates

Practical clinician messaging (ready-to-use lines)

  • “Finasteride can cause depressive symptoms, including suicidal thoughts. If you or someone you care for develops worsening mood or thoughts of self-harm, stop the medicine (for 1 mg) and seek medical help immediately.” European Medicines Agency (EMA)
  • “Discuss your mental health history before starting finasteride; if you have a history of depression or suicidal ideation, consider alternative options.” Medscape

Areas of controversy & national positions

  • Some national agencies or interest groups (e.g., in Belgium, France) expressed concern that proposed measures may be insufficient and called for stricter steps. Expect local differences in implementation and potentially additional national warnings or monitoring requirements. Manufacturers must track member-state responses and adjust country-specific materials. famhp.bePFS Foundation

Final assessment & timeline

  • Immediate (0–2 weeks): implement DHPC, patient alert card insertion for 1 mg packs, expedite SmPC/PIL submission drafts to regulators, begin intensified ICSR follow-up. European Medicines Agency (EMA)
  • Short term (2–12 weeks): run O/E and disproportionality analyses, launch prospective registry setup and initial epidemiology contracts, update RMP/PSUR. PMC
  • Medium term (3–12 months): deliver SCCS/cohort study results, mechanistic research planning, produce consolidated risk assessment for regulators. PMC

Sources & further reading

Contact us: company@shudarsana.com

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.

error: Content is protected !!